ライフサイエンスコーパス: 2-amino-4-phosphonobutyric acid

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 intravitreal injections of L-AP4 (not APB) (2-amino-4-phosphonobutyric acid, 1.6-2.0 mM), to prevent

2 ctivated by the group III-specific agonist L-2-amino-4-phosphonobutyric acid; (2(S), 1'(S), 2'(S)]- 2

3 In wild-type (WT) mice, APB (DL-2-amino-4-phosphonobutyric acid), an mGluR6 agonist, blo

4 tion of oxygen consumption, was blocked by L-2-amino-4-phosphonobutyric acid and kynurenic acid.

5 r the inhibitory amino acid GABA and after L-2 amino-4-phosphonobutyric acid (APB) to block signal tr

6 GABA) to block all inner retinal activity; L-2 amino-4-phosphonobutyric acid (APB) to block the On-pa

7 efore and after intravitreal injection of DL-2-amino-4-phosphonobutyric acid (APB) and cis-2, 3-piper

8 Intravitreal injections of DL-2-amino-4-phosphonobutyric acid (APB) and cis-2,3-piperi

9 We made intraocular injections of 2-amino-4-phosphonobutyric acid (APB) in adult cats to b

10 The glutamate analog, 2-amino-4-phosphonobutyric acid (APB) is a proven tool i

11 h Erev approximately 0 mV, mimicked by L-(+)-2-amino-4-phosphonobutyric acid (APB) or trans-1-amino-1

12 The glutamate agonist, 2-amino-4-phosphonobutyric acid (APB) was used to examin

13 otropic glutamate receptor (mGluR6) agonist, 2-amino-4-phosphonobutyric acid (APB), and/or the ionotr

14 One eye was injected with 2-amino-4-phosphonobutyric acid (APB), which is known to

15 duced by daily intravitreal injections of DL-2-amino-4-phosphonobutyric acid (APB).

16 kainate-selective agonist SYM 2081 or by DL-2-amino-4-phosphonobutyric acid (DL-AP4).

17 ion potentials (tetrodotoxin inhibits, (+/-)-2-amino-4-phosphonobutyric acid enhances), P/Q-type VDCC

18 rate) and the group III agonist L-AP4 (L-(+)-2-amino-4-phosphonobutyric acid) failed to alter the lev

19 -(carboxycyclopropyl)glycine approximately L-2-amino-4-phosphonobutyric acid > glutamate > > [1(S), 3

20 rmore, PHCCC potentiated the effect of l-(+)-2-amino-4-phosphonobutyric acid in inhibiting transmissi

21 xylate] (0.1 mum) or group III agonist l-(+)-2-amino-4-phosphonobutyric acid (l-AP-4) (10 mum) blocke

22 The mGluR agonist l-(+)-2-amino-4-phosphonobutyric acid (l-AP-4) inhibited synap

23 of the mGlu(7) agonists glutamate and L-(+)-2-Amino-4-phosphonobutyric acid (L-AP4) in the presence

24 The group III mGluR-selective agonist L-(+)-2-amino-4-phosphonobutyric acid (L-AP4) inhibited these

25 II metabotropic glutamate receptor agonist L-2-amino-4-phosphonobutyric acid (L-AP4) produced an incr

26 xy-3-hydroxyphenylglycine (4C3HPG) and L-(+)-2-amino-4-phosphonobutyric acid (L-AP4), agonists for gr

27 rrogate agonists, such as the compound L-(+)-2-Amino-4-phosphonobutyric acid (L-AP4), are often used

28 f 21 microM, and the Group III agonist, L(+)-2-amino-4-phosphonobutyric acid (L-AP4), decreased the e

29 yrrolidine-2,4-dicarboxylate (APDC) and L(+)-2-amino-4-phosphonobutyric acid (L-AP4), respectively) d

30 The group III agonist, l-(+)-2-Amino-4-phosphonobutyric acid (l-AP4), slightly decrea

31 ) or with the mGluR4 selective agonist L-(+)-2-amino-4-phosphonobutyric acid (L-AP4); however, full a

32 not by the group III-preferring agonist L(+)-2-amino-4-phosphonobutyric acid (L-AP4); it was blocked

33 ne-2,3-dicarboxylate] and III [L-AP 4 (L-(+)-2-amino-4-phosphonobutyric acid)], mGluR agonists, an IP